Healing & Repair
GHK-Cu (Copper Tripeptide-1)
← Back to Library
Limited / unverified FDA safety flag Limited / unverified Repair Longevity
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 50, 100 mg
Dosing window: Anytime
Receptor / target: MMP; DNA Repair
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
| Weeks 5-8 | 1.5mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
| Weeks 9-12+ | 2mg 1x Daily | 5 Days on, 2 Days Off. Rotate injection sites frequently due to bruising. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative 1: The BPC Blend Buffer
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1.5mg GHK-Cu + 250mcg BPC-157 | Pulling BPC-157 into the same syringe as GHK-Cu acts as a buffer, almost entirely eliminating the severe injection site sting. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative 2: 8-Week Daily Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1mg 1x/day | 7 days/week. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (MMP; DNA Repair); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. The copper fear is usually overstated, but not imaginary. GHK-Cu is not pure copper; 4 mg is roughly under 1 mg elemental copper, while the adult oral copper UL is 10 mg/day from food and supplements. Injection route, baseline copper status, Wilson's disease, liver disease, and total dietary/supplement copper still matter. Do not add zinc reflexively; excess zinc can lower copper status and should be based on labs or clinician guidance.
Independent evidence
Independent safety notes: FDA lists injectable GHK-Cu among withdrawn nominated bulk substances with limited human safety data. Copper toxicity concerns should be framed around total elemental copper, route, and copper-handling disorders; reflex zinc supplementation is not supported and excess zinc can reduce copper status.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Wilson's disease or other genetic copper metabolism disorders: the copper component of GHK-Cu bypasses normal hepatic copper regulation; copper accumulation in subjects with impaired copper transport (ATP7B mutations) is a serious risk. Limited / unverified
- Known copper hypersensitivity or copper allergy: systemic injection of a copper complex in a hypersensitive subject may provoke significant immune reactions. Limited / unverified
- Active malignancy: GHK-Cu promotes angiogenesis via VEGF/VEGFR2 upregulation; while preclinical data suggests anti-metastatic gene regulation, the pro-angiogenic mechanism remains a contraindication in subjects with active tumors. Limited / unverified
- Pregnancy: no human safety data; copper homeostasis is tightly regulated during fetal development; avoid. Limited / unverified
- Breastfeeding: no established safety data. Limited / unverified
- Known hypersensitivity to GHK-Cu or peptide excipients. Limited / unverified
- Copper-chelating drugs (for example penicillamine or trientine) and pharmacologic zinc used specifically to lower copper may interfere with the active copper complex. Do not add zinc simply to 'balance' GHK-Cu; high-dose zinc can lower copper status and should be based on labs or clinician guidance. Source-supported caution
- Hemochromatosis or iron overload disorders: impaired metal metabolism may affect copper handling. Limited / unverified
- Individuals with elevated baseline serum copper levels: risk of copper toxicity at systemic injectable doses. Limited / unverified
Side effects (limited evidence)
- Severe Post-Injection Pain (PIP): the defining adverse effect of subcutaneous GHK-Cu; caused by the copper ion reacting with subcutaneous tissue; characterized by burning, stinging, redness, and welts at the injection site; intensity varies by concentration, volume, and injection location; nearly eliminated by co-injecting with BPC-157. Limited / unverified
- Bruising and hematoma formation at injection sites: particularly with daily protocols; mandatory site rotation mitigates this but does not eliminate it. Limited / unverified
- Local redness and induration: tissue response to copper deposition; resolves between injection sessions; the 5-on/2-off schedule provides recovery time. Limited / unverified
- Copper toxicity fear check: adult oral copper UL is 10 mg/day from food and supplements, and GHK-Cu is not pure copper (4 mg is roughly under 1 mg elemental copper). That does not make injection risk zero: route, total copper exposure, liver disease, Wilson's disease, elevated baseline copper, and chronic high-dose use still matter. Source-supported caution
- "Copper uglies": a rare paradoxical effect where excessive MMP-1 stimulation at high concentrations causes collagen fragmentation rather than synthesis, resulting in apparent skin quality degradation; primarily documented anecdotally in topical overuse; not formally documented at injectable doses. Limited / unverified
- Mild systemic fatigue: occasionally reported in first 1-2 weeks of use; likely related to initial tissue remodeling signal load. Limited / unverified
- Headache: uncommon; possibly related to VEGF-mediated vasodilation. Limited / unverified
- Temporary melanin increase at injection sites: tyrosinase activation from copper delivery can produce local hyperpigmentation; resolves over weeks after cessation. Limited / unverified
- Nausea: rare; may be copper-related at higher doses. Limited / unverified
- Potential MMP overactivation at supraphysiological concentrations: theoretical; context-dependent MMP regulation can shift from constructive to destructive at excessive doses. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
Sources
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
- https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/
- https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/